VLON: Vallon Pharmaceuticals, Inc. - Summary | Jitta

Vallon Pharmaceuticals, Inc.

NASDAQ:VLON

Notice
Stock data is unavailable or the company’s delisted.
Price
$6.70
Loss Chance
58.4%
0.78JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (9)
Recent Business Performance (33)
Financial Strength (29)
Return to Shareholders (0)
Competitive Advantage (8)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.78
100.00%
2.03
316.59%
2.03
316.59%
4.41
53.66%
3.32
38.04%
2.67
16.43%
COMPANY DESCRIPTION
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company’s lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.